Please note that this product was withdrawn from the Union Register of orphan medicinal products in October 2021 on request of the sponsor.
On 13 November 2013, orphan designation (EU/3/13/1203) was granted by the European Commission to Janssen-Cilag International N.V., Belgium, for ibrutinib for the treatment of diffuse large B-cell lymphoma.
Treatment of diffuse large B-cell lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: